Who is sponsoring NCT02993991?

NCT02993991 is sponsored by University Health Network, Toronto.

What drugs are being tested in NCT02993991?

Interventions in NCT02993991: Mocetinostat, Durvalumab.

What condition does NCT02993991 study?

NCT02993991 studies Squamous Cell Carcinoma, Head And Neck, Squamous Cell Carcinoma Mouth, Resectable Squamous Cell Carcinoma of Oral Cavity.

Is NCT02993991 still recruiting?

NCT02993991 is currently withdrawn. Last updated 29 December 2017.

Last reviewed 2017-12-29 · How we verify

NCT02993991: PRIMED-001

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Pre-operative Mocetinostat (MGCD0103) and Durvalumab (MEDI4736) (PRIMED) for Squamous Cell Carcinoma of the Oral Cavity

Withdrawn Phase 1 Last updated 29 December 2017

What this trial tests

Phase 1 trial testing Mocetinostat in Squamous Cell Carcinoma, Head And Neck. Withdrawn.

Timeline

10 October 2017

Primary endpoint
21 December 2017

21 December 2017

Quick facts

Lead sponsor	University Health Network, Toronto
Phase	Phase 1
Status	Withdrawn
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Start date	10 October 2017
Primary completion	21 December 2017
Estimated completion	21 December 2017
Sites	1 location across Canada

Drugs / interventions tested

Mocetinostat — full drug profile →
Durvalumab — full drug profile →

Conditions studied

Squamous Cell Carcinoma, Head And Neck — all drugs for Squamous Cell Carcinoma, Head And Neck →
Squamous Cell Carcinoma Mouth — all drugs for Squamous Cell Carcinoma Mouth →
Resectable Squamous Cell Carcinoma of Oral Cavity — all drugs for Resectable Squamous Cell Carcinoma of Oral Cavity →

Sponsor

University Health Network, Toronto

Who can join

18 and older, any sex, with Squamous Cell Carcinoma, Head And Neck or Squamous Cell Carcinoma Mouth. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This is a Phase 1 Window of Opportunity study to evaluate the pharmacodynamic and immune effects of pre-operative therapy with Mocetinostat and Durvalumab on patients with squamous cell carcinoma of the oral cavity.

Publications & conference data

7 peer-reviewed publications reference this trial (live from Europe PMC):

Epigenetics-targeted drugs: current paradigms and future challenges.
Dai W, Qiao X, Fang Y, Guo R, et al · · 2024 · cited 131× · PMID 39592582 · DOI 10.1038/s41392-024-02039-0
Epi-drugs in combination with immunotherapy: a new avenue to improve anticancer efficacy.
Mazzone R, Zwergel C, Mai A, Valente S. · · 2017 · cited 113× · PMID 28572863 · DOI 10.1186/s13148-017-0358-y
Checkpoint immunotherapy in head and neck cancers.
Zolkind P, Uppaluri R. · · 2017 · cited 36× · PMID 28836124 · DOI 10.1007/s10555-017-9694-9
Epi-immunotherapy for cancers: rationales of epi-drugs in combination with immunotherapy and advances in clinical trials.
Xu Y, Li P, Liu Y, Xin D, et al · · 2022 · cited 29× · PMID 35642676 · DOI 10.1002/cac2.12313
Combination therapy with PD-1/PD-L1 blockade: An overview of ongoing clinical trials.
Johnson CB, Win SY. · · 2018 · cited 26× · PMID 29632719 · DOI 10.1080/2162402x.2017.1408744
Autoimmune disease: a view of epigenetics and therapeutic targeting.
Mu S, Wang W, Liu Q, Ke N, et al · · 2024 · cited 21× · PMID 39606248 · DOI 10.3389/fimmu.2024.1482728
Leveraging Genomics for Head and Neck Cancer Treatment.
Kemmer JD, Johnson DE, Grandis JR. · · 2018 · cited 8× · PMID 29420101 · DOI 10.1177/0022034518756352

Verify or expand the search:

Other trials of Mocetinostat

Trials testing the same drug.

NCT04299113 — Mocetinostat With Vinorelbine in Children, Adolescents & Young Adults With Refractory and/or Recurrent Rhabdomyosarcoma · Phase 1 · active not recruiting
NCT02954991 — Phase 2 Study of Glesatinib, Sitravatinib or Mocetinostat in Combination With Nivolumab in Non-Small Cell Lung Cancer · Phase 2 · terminated

Other recruiting trials for Squamous Cell Carcinoma, Head And Neck

Currently open trials in the same condition.

NCT06736379 — Intratumoral Delivery of Viral Replicon (saRNA) Particles Expressing IL-12 in Head and Neck Cancer · Phase 1 · recruiting

Other University Health Network, Toronto trials

Trials by the same sponsor.

NCT06831032 — Elective Adaptive Radiation With SBRT for Improved DurabilitY of Response · NA · recruiting
NCT06634056 — Pneumonitis Prevention Protocol Using Pentoxifylline and α-tocopherol In Stage III Non-Small Cell Lung Cancer Patients U · Phase 2 · not yet recruiting
NCT06836726 — Clinical Trial to Test Efficacy of Targeting Hypoxia Combined With ARSI After First-line ARSI Therapy for Castrate Resis · Phase 2 · not yet recruiting
NCT07515651 — Molecular Imaging Informed Radiation Dose Escalation to Sites of Recurrent Disease and De-escalation to Uninvolved Areas · Phase 2 · not yet recruiting
NCT07509450 — Fecal Microbiota Transplantation in Patients Undergoing Chimeric Antigen Receptor T-cell Therapy and Allogeneic Stem Cel · NA · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT02993991 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by University Health Network, Toronto
Last refreshed: 29 December 2017

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02993991.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing